CTA 056 |
| カタログ番号GC50076 |
CTA 056 は、IC50 が 0.1 μM の ITK (IL-2 誘導性 T 細胞キナーゼ) 阻害剤です。 CTA 056 は、悪性 T 細胞を選択的に標的とし、オンコミアを調節します。 CTA 056 はアポトーシスを誘導し、T 細胞性白血病およびリンパ腫の治療薬となる可能性があります。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1265822-30-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Interleukin-2-inducible T-cell kinase (ITK) inhibitor (IC50 values are 0.1, 0.4 and 5 μM for ITK, BTK and ETK, respectively). Inhibits growth of cancer cells expressing ITK, including MOLT-4 and Jurkat cells in vitro. Induces apoptosis in Jurkat cells. Inhibits MOLT-4 xenograft tumor growth in mice.
Guo et al (2012) Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol.Pharmacol. 82 938 PMID:22899868
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *